SML1913

ASB14780

≥98% (HPLC)

• Synonym(e): 3-(3-Phenethyl-1-(4-phenoxyphenyl)-1H-indol-5-yl)propanoic acid, 2-amino-2-(hydroxymethyl)-1,3-propanediol, 3-[1-(4-Phenoxyphenyl)-3-(2-phenylethyl)-1H-indol-5-yl]propanoic acid, 2-amino-2-(hydroxymethyl)-1,3-propanediol
• Empirische Formel (Hill-System): C₃₁H₂₇NO₃ · C₄H₁₁NO₃
• CAS-Nummer: 1069046-00-9
• Molekulargewicht: 582.69
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 10 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: O=C(O)CCC1=CC2=C(N(C3=CC=C(OC4=CC=CC=C4)C=C3)C=C2CCC5=CC=CC=C5)C=C1.NC(CO)(CO)CO

Beschreibung

Biochem./physiol. Wirkung

ASB14780 can be a potential therapeutic for the treatment of asthma and other pulmonary diseases. In addition, its inhibitory function on group IVA phospholipase A2 (IVA-PLA2) qualifies this drug to be a potential candidate for the treatment of non-alcoholic fatty liver diseases.

ASB14780 is an indole-based selective and potent cytosolic phospholipase A₂α inhibitor (IC₅₀ = 20 nM/cPLA₂α and >10 μM/sPLA₂α). ASB14780 inhibits cPLA₂α-dependent inflammatory responses both in cultures and in animals in vivo, including LPS-induced PGE2 production (IC₅₀ = 0.5 μM; mouse peritoneal exudate cells), A23187-induced TXB2 production (IC₅₀ = 0.54 and 0.64 μM using guinea pig and human whole blood, respectively), TPA-induced ear edema (50 mg/kg, p.o.; mice), OVA-induced asthma (5 - 20 mg/kg/d, p.o.; guinea pig), CCl4-induced hepatic fibrosis and high-fat cholesterol diet-induced fatty liver (0.1-0.3 g/kg/d, p.o.; mouse). SB14780 bioavailability is also demonstrated in dog and monkey, albeit at a lower value (F = 34.3%/dog and 30.9%/monkey vs. 89.6%/mouse).

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable